Platelet-activating factor increases lung vascular permeability to protein

K. E. Burhop, Joe GN Garcia, W. M. Selig, S. K. Lo, H. van der Zee, J. E. Kaplan, A. B. Malik

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

We studied the effects of platelet-activating factor (PAF) on pulmonary hemodynamics and microvascular permeability in unanesthetized sheep prepared with lung-lymph fistulas. Since cyclooxygenase metabolites have been implicated in mediating these responses, we also examined the role of the cyclooxygenase pathway. PAF infusion (4 μg·kg-1·h-1 for 3 h) produced a rapid, transient rise in pulmonary arterial pressure (Ppa), pulmonary vascular resistance (PVR), plasma thromboxane B2 concentration (TxB2), and pulmonary lymph flow (Q̇lym). The lymph-to-plasma protein concentration ratio (L/P) did not change from base line. Pretreatment with the cyclooxygenase inhibitor, sodium meclofenamate, prevented the generation of TxB2 and the hemodynamic changes but did not prevent the increase in Q̇lym. The estimated protein reflection coefficient decreased from a control value of 0.66 ± 0.04 to 0.43 ± 0.06 after PAF infusion. We also studied the effects of PAF on endothelial permeability in vitro by measuring the flux of 125I-albumin across cultured bovine pulmonary artery endothelial cells (EC) grown to confluency on a gelatinized micropore filter and mounted within a modified Boyden chemotaxis chamber. PAF (10-8 to 10-4 M) had no direct effect on EC albumin permeability, suggesting that the increase in permeability in sheep was not the direct lytic effect of PAF. In conclusion, PAF produces pulmonary vasoconstriction mediated by cyclooxygenase metabolites. PAF also increases pulmonary vascular permeability to protein that is independent of cyclooxygenase products and is not the result of a direct effect of PAF on the endothelium.

Original languageEnglish (US)
Pages (from-to)2210-2217
Number of pages8
JournalJournal of Applied Physiology
Volume61
Issue number6
StatePublished - 1986
Externally publishedYes

Fingerprint

Platelet Activating Factor
Capillary Permeability
Lung
Prostaglandin-Endoperoxide Synthases
Proteins
Lymph
Permeability
Thromboxane B2
Albumins
Sheep
Endothelial Cells
Hemodynamics
Micropore Filters
Meclofenamic Acid
Cyclooxygenase Inhibitors
Chemotaxis
Vasoconstriction
Vascular Resistance
Pulmonary Artery
Fistula

ASJC Scopus subject areas

  • Physiology
  • Endocrinology
  • Orthopedics and Sports Medicine
  • Physical Therapy, Sports Therapy and Rehabilitation

Cite this

Burhop, K. E., Garcia, J. GN., Selig, W. M., Lo, S. K., van der Zee, H., Kaplan, J. E., & Malik, A. B. (1986). Platelet-activating factor increases lung vascular permeability to protein. Journal of Applied Physiology, 61(6), 2210-2217.

Platelet-activating factor increases lung vascular permeability to protein. / Burhop, K. E.; Garcia, Joe GN; Selig, W. M.; Lo, S. K.; van der Zee, H.; Kaplan, J. E.; Malik, A. B.

In: Journal of Applied Physiology, Vol. 61, No. 6, 1986, p. 2210-2217.

Research output: Contribution to journalArticle

Burhop, KE, Garcia, JGN, Selig, WM, Lo, SK, van der Zee, H, Kaplan, JE & Malik, AB 1986, 'Platelet-activating factor increases lung vascular permeability to protein', Journal of Applied Physiology, vol. 61, no. 6, pp. 2210-2217.
Burhop KE, Garcia JGN, Selig WM, Lo SK, van der Zee H, Kaplan JE et al. Platelet-activating factor increases lung vascular permeability to protein. Journal of Applied Physiology. 1986;61(6):2210-2217.
Burhop, K. E. ; Garcia, Joe GN ; Selig, W. M. ; Lo, S. K. ; van der Zee, H. ; Kaplan, J. E. ; Malik, A. B. / Platelet-activating factor increases lung vascular permeability to protein. In: Journal of Applied Physiology. 1986 ; Vol. 61, No. 6. pp. 2210-2217.
@article{08679145dbf744eb94b72f624da880dd,
title = "Platelet-activating factor increases lung vascular permeability to protein",
abstract = "We studied the effects of platelet-activating factor (PAF) on pulmonary hemodynamics and microvascular permeability in unanesthetized sheep prepared with lung-lymph fistulas. Since cyclooxygenase metabolites have been implicated in mediating these responses, we also examined the role of the cyclooxygenase pathway. PAF infusion (4 μg·kg-1·h-1 for 3 h) produced a rapid, transient rise in pulmonary arterial pressure (Ppa), pulmonary vascular resistance (PVR), plasma thromboxane B2 concentration (TxB2), and pulmonary lymph flow (Q̇lym). The lymph-to-plasma protein concentration ratio (L/P) did not change from base line. Pretreatment with the cyclooxygenase inhibitor, sodium meclofenamate, prevented the generation of TxB2 and the hemodynamic changes but did not prevent the increase in Q̇lym. The estimated protein reflection coefficient decreased from a control value of 0.66 ± 0.04 to 0.43 ± 0.06 after PAF infusion. We also studied the effects of PAF on endothelial permeability in vitro by measuring the flux of 125I-albumin across cultured bovine pulmonary artery endothelial cells (EC) grown to confluency on a gelatinized micropore filter and mounted within a modified Boyden chemotaxis chamber. PAF (10-8 to 10-4 M) had no direct effect on EC albumin permeability, suggesting that the increase in permeability in sheep was not the direct lytic effect of PAF. In conclusion, PAF produces pulmonary vasoconstriction mediated by cyclooxygenase metabolites. PAF also increases pulmonary vascular permeability to protein that is independent of cyclooxygenase products and is not the result of a direct effect of PAF on the endothelium.",
author = "Burhop, {K. E.} and Garcia, {Joe GN} and Selig, {W. M.} and Lo, {S. K.} and {van der Zee}, H. and Kaplan, {J. E.} and Malik, {A. B.}",
year = "1986",
language = "English (US)",
volume = "61",
pages = "2210--2217",
journal = "Journal of Applied Physiology",
issn = "8750-7587",
publisher = "American Physiological Society",
number = "6",

}

TY - JOUR

T1 - Platelet-activating factor increases lung vascular permeability to protein

AU - Burhop, K. E.

AU - Garcia, Joe GN

AU - Selig, W. M.

AU - Lo, S. K.

AU - van der Zee, H.

AU - Kaplan, J. E.

AU - Malik, A. B.

PY - 1986

Y1 - 1986

N2 - We studied the effects of platelet-activating factor (PAF) on pulmonary hemodynamics and microvascular permeability in unanesthetized sheep prepared with lung-lymph fistulas. Since cyclooxygenase metabolites have been implicated in mediating these responses, we also examined the role of the cyclooxygenase pathway. PAF infusion (4 μg·kg-1·h-1 for 3 h) produced a rapid, transient rise in pulmonary arterial pressure (Ppa), pulmonary vascular resistance (PVR), plasma thromboxane B2 concentration (TxB2), and pulmonary lymph flow (Q̇lym). The lymph-to-plasma protein concentration ratio (L/P) did not change from base line. Pretreatment with the cyclooxygenase inhibitor, sodium meclofenamate, prevented the generation of TxB2 and the hemodynamic changes but did not prevent the increase in Q̇lym. The estimated protein reflection coefficient decreased from a control value of 0.66 ± 0.04 to 0.43 ± 0.06 after PAF infusion. We also studied the effects of PAF on endothelial permeability in vitro by measuring the flux of 125I-albumin across cultured bovine pulmonary artery endothelial cells (EC) grown to confluency on a gelatinized micropore filter and mounted within a modified Boyden chemotaxis chamber. PAF (10-8 to 10-4 M) had no direct effect on EC albumin permeability, suggesting that the increase in permeability in sheep was not the direct lytic effect of PAF. In conclusion, PAF produces pulmonary vasoconstriction mediated by cyclooxygenase metabolites. PAF also increases pulmonary vascular permeability to protein that is independent of cyclooxygenase products and is not the result of a direct effect of PAF on the endothelium.

AB - We studied the effects of platelet-activating factor (PAF) on pulmonary hemodynamics and microvascular permeability in unanesthetized sheep prepared with lung-lymph fistulas. Since cyclooxygenase metabolites have been implicated in mediating these responses, we also examined the role of the cyclooxygenase pathway. PAF infusion (4 μg·kg-1·h-1 for 3 h) produced a rapid, transient rise in pulmonary arterial pressure (Ppa), pulmonary vascular resistance (PVR), plasma thromboxane B2 concentration (TxB2), and pulmonary lymph flow (Q̇lym). The lymph-to-plasma protein concentration ratio (L/P) did not change from base line. Pretreatment with the cyclooxygenase inhibitor, sodium meclofenamate, prevented the generation of TxB2 and the hemodynamic changes but did not prevent the increase in Q̇lym. The estimated protein reflection coefficient decreased from a control value of 0.66 ± 0.04 to 0.43 ± 0.06 after PAF infusion. We also studied the effects of PAF on endothelial permeability in vitro by measuring the flux of 125I-albumin across cultured bovine pulmonary artery endothelial cells (EC) grown to confluency on a gelatinized micropore filter and mounted within a modified Boyden chemotaxis chamber. PAF (10-8 to 10-4 M) had no direct effect on EC albumin permeability, suggesting that the increase in permeability in sheep was not the direct lytic effect of PAF. In conclusion, PAF produces pulmonary vasoconstriction mediated by cyclooxygenase metabolites. PAF also increases pulmonary vascular permeability to protein that is independent of cyclooxygenase products and is not the result of a direct effect of PAF on the endothelium.

UR - http://www.scopus.com/inward/record.url?scp=0022858936&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022858936&partnerID=8YFLogxK

M3 - Article

C2 - 3804927

AN - SCOPUS:0022858936

VL - 61

SP - 2210

EP - 2217

JO - Journal of Applied Physiology

JF - Journal of Applied Physiology

SN - 8750-7587

IS - 6

ER -